Learn

Sodium glucose cotransporter 2 (SGLT2) inhibitors, such as empagliflozin, dapagliflozin, ertugliflozin and canagliflozin, increase urinary excretion of glucose by inhibiting reabsorption from renal proximal tubules. Glycaemic, cardiovascular and renal benefits of SGLT2 inhibitors have propelled their popularity.

They are an established treatment for type 2 diabetes, heart failure with reduced or preserved ejection fraction, and chronic kidney disease, irrespective of diabetes status.

This MJA perspective shares more.

Learning Outcomes

1. Explain key components of the perspective
2. List main findings
3. Differentiate patients with and without diabetes to avoid unnecessary procedures.

Details

Author: Lisa M Raven, Christopher A Muir and Jerry R Greenfield

Article Type: Perspective